trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['solid tumor', 'pantumor', 't-dxd']
her2 is a relevant target in many tumor types in destiny-pantumor02, t-dxd showed activity across her2 expressing many solid tumors orr 37.1% in all patients and 61.3% in patients with ihc 3+ with dor 11.8 months in all patients and 22.1 months in patients with ihc 3+! #asco23 
Thoracic Medical Oncologist at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM